Heartbeam, Inc.

Greetings, and welcome to the HeartBeam First Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would now like to hand the call over to Larry Holub, Director at MZ Group. Larry?

Good afternoon and welcome to HeartBeam's financial results call. Today's conference call is being recorded. Before we begin the formal presentation, I would like to remind everyone that statements made on the call and webcast may include predictions, estimates, or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revisions to these forward-looking statements in light of new information or future events. Throughout today's discussion, we will attempt to present some important factors relating to our business that may affect our predictions. You should also review our most recent Form 10-K and Form 10-Q for a more complete discussion of these factors and other risks, particularly under the heading Risk Factors. A press release detailing these results crossed the wire this afternoon at 4.01 p.m. Eastern Time and is available in the Investor Relations section of our company's website, heartbeam.com. Your host today, Branislav Vodic. Chief Executive Officer and Founder, John Hunt, Chief Business Officer, and Rick Brownstein, Chief Financial Officer, will present results of operations for the first quarter ended March 31st, 2022. At this time, I will turn the call over to Harpy Chief Executive Officer, Branislav Vaid.

Thank you, Larry, and good afternoon, everyone. I'm pleased to welcome you to today's first quarter 2022 financial results conference call. Our first quarter was highlighted by continued momentum in our product development timeline, empowered by multiple strategic partnerships to advance commercialization. During the quarter, we established our scientific advisory board with appointment of world-renowned cardiologist, Dr. Mike Gibson, as chairman to drive success in the use of our technologies. And we have further rounded out our capabilities with additional staff in sales, IT and cybersecurity, QA, document control, support in electronic UMS, technical support, customer support, and accounting. We have also signed agreements with Livemore and Triple Ring Technologies that will help bring our technologies to commercialization. Our commercial team has identified key target accounts for both the HeartBeam ED and telehealth product and have engaged in a number of productive discussions on partnering with these key institutions. The target accounts include large academic institutions, regional healthcare systems in the Southeast, Mid-Atlantic, and regional community systems in the Western U.S. Some of these include Piedmont, Health, Wellstar, Emory, Atrium Wake Forest, WellSpan Health, UCLA, Harborview, and Centura. Overall, there has been a very positive response to our technology, and several systems are willing to conduct pilot evaluations of our ED software solution as soon as we receive FDA clearance for the product. Goal for the commercial team is to transition the participating centers to a revenue account at the conclusion of the pilot evaluation. We look forward to ongoing conversations with these healthcare leaders moving forward. By developing our proprietary 3D vector signal-based technology, we have addressed a huge unmet need and an enormous market opportunity. Most of you are familiar with the market for atrial fibrillation or AFib detection and key players in that space. That market size is defined by the prevalence of AFib patients in the U.S. There are about 3 million AFib patients in the United States. It is estimated to be a $2 billion market. AFib detection space has many players, and some of the leaders are AliveCore and Apple with their Apple Watch. The market for heart attack detection outside of medical facility is much larger. It is determined by about 18 million people in the United States that are at high risk for a heart attack. That is, in our estimate, a market that exceeds $10 billion in the U.S. only. Of particular interest to us, and we believe the early adopters will be individuals that are survivors of a heart attack. There are about 8 million people in the U.S. that fall into this category. They are at super high risk for another heart attack, and indeed, we believe that these individuals and their cardiologists will be leading the adoption of our telehealth technologies. The telehealth space is a rapidly emerging solution that has dramatically increased with the onset of COVID-19 and is being driven by government policies to promote its use, along with the rise of chronic conditions and an aging population. Indeed, we are seeing at so many levels that patient care is moving to the patients and outside of the four walls of a medical institution. We believe that this trend will only accelerate. Again, bringing our telehealth product to cardiac patients and their physicians will present a major advancement for cardiovascular patient care. Cardiovascular illnesses remain number one cause of death in the U.S. and present a huge telehealth market opportunity. I would now like to turn the call over to John Hunt, our Chief Business Officer, to further discuss our products and commercialization plans. John.